JP6045347B2 - ラサギリンの持続放出性製剤およびその使用 - Google Patents

ラサギリンの持続放出性製剤およびその使用 Download PDF

Info

Publication number
JP6045347B2
JP6045347B2 JP2012551732A JP2012551732A JP6045347B2 JP 6045347 B2 JP6045347 B2 JP 6045347B2 JP 2012551732 A JP2012551732 A JP 2012551732A JP 2012551732 A JP2012551732 A JP 2012551732A JP 6045347 B2 JP6045347 B2 JP 6045347B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rasagiline
total weight
pellets
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012551732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518870A5 (cg-RX-API-DMAC10.html
JP2013518870A (ja
Inventor
ヨラム セラ
ヨラム セラ
ヌリット リヴナア
ヌリット リヴナア
イチャック ラメンスドルフ
イチャック ラメンスドルフ
トメール マドモン
トメール マドモン
Original Assignee
ファーマ ツー ビー リミテッド
ファーマ ツー ビー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43896855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6045347(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ファーマ ツー ビー リミテッド, ファーマ ツー ビー リミテッド filed Critical ファーマ ツー ビー リミテッド
Publication of JP2013518870A publication Critical patent/JP2013518870A/ja
Publication of JP2013518870A5 publication Critical patent/JP2013518870A5/ja
Application granted granted Critical
Publication of JP6045347B2 publication Critical patent/JP6045347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012551732A 2010-02-03 2011-02-03 ラサギリンの持続放出性製剤およびその使用 Active JP6045347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30101910P 2010-02-03 2010-02-03
US61/301,019 2010-02-03
PCT/IL2011/000126 WO2011095973A1 (en) 2010-02-03 2011-02-03 Extended release formulations of rasagiline and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016186945A Division JP6440662B2 (ja) 2010-02-03 2016-09-26 ラサギリンの持続放出性製剤およびその使用

Publications (3)

Publication Number Publication Date
JP2013518870A JP2013518870A (ja) 2013-05-23
JP2013518870A5 JP2013518870A5 (cg-RX-API-DMAC10.html) 2014-03-20
JP6045347B2 true JP6045347B2 (ja) 2016-12-14

Family

ID=43896855

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012551732A Active JP6045347B2 (ja) 2010-02-03 2011-02-03 ラサギリンの持続放出性製剤およびその使用
JP2016186945A Active JP6440662B2 (ja) 2010-02-03 2016-09-26 ラサギリンの持続放出性製剤およびその使用
JP2018216973A Active JP6770564B2 (ja) 2010-02-03 2018-11-20 ラサギリンの持続放出性製剤およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016186945A Active JP6440662B2 (ja) 2010-02-03 2016-09-26 ラサギリンの持続放出性製剤およびその使用
JP2018216973A Active JP6770564B2 (ja) 2010-02-03 2018-11-20 ラサギリンの持続放出性製剤およびその使用

Country Status (25)

Country Link
US (1) US9943489B2 (cg-RX-API-DMAC10.html)
EP (2) EP2531181B1 (cg-RX-API-DMAC10.html)
JP (3) JP6045347B2 (cg-RX-API-DMAC10.html)
KR (1) KR101791715B1 (cg-RX-API-DMAC10.html)
CN (1) CN102791258B (cg-RX-API-DMAC10.html)
AU (1) AU2011212068B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012019374B1 (cg-RX-API-DMAC10.html)
CA (1) CA2789006C (cg-RX-API-DMAC10.html)
CL (1) CL2012002175A1 (cg-RX-API-DMAC10.html)
CY (1) CY1121781T1 (cg-RX-API-DMAC10.html)
DK (1) DK2531181T3 (cg-RX-API-DMAC10.html)
ES (1) ES2733133T3 (cg-RX-API-DMAC10.html)
HU (1) HUE044221T2 (cg-RX-API-DMAC10.html)
IL (1) IL221274A (cg-RX-API-DMAC10.html)
LT (1) LT2531181T (cg-RX-API-DMAC10.html)
MX (1) MX354423B (cg-RX-API-DMAC10.html)
NZ (1) NZ602111A (cg-RX-API-DMAC10.html)
PL (1) PL2531181T3 (cg-RX-API-DMAC10.html)
PT (1) PT2531181T (cg-RX-API-DMAC10.html)
RS (1) RS58988B1 (cg-RX-API-DMAC10.html)
RU (2) RU2734632C2 (cg-RX-API-DMAC10.html)
SG (1) SG183150A1 (cg-RX-API-DMAC10.html)
TR (1) TR201909277T4 (cg-RX-API-DMAC10.html)
WO (1) WO2011095973A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201206462B (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031189A (ja) * 2010-02-03 2017-02-09 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2758556A1 (en) * 2011-11-17 2013-05-17 Pharmascience Inc. Pharmaceutical composition of amphetamine mixed salts
JP6243351B2 (ja) * 2012-01-12 2017-12-06 ファーマ ツゥ ビー リミテッド パーキンソン病の固定投与量薬剤組合せ治療
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
EP2829270B1 (en) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Joint product containing synephrine and topiramate
CN102579367B (zh) * 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline
US20150275167A1 (en) * 2014-03-28 2015-10-01 Corning Incorporated Composition and method for cell culture sustained release
US10709700B2 (en) * 2014-09-15 2020-07-14 Orphazyme A/S Arimoclomol formulation
WO2018213838A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
CN107049985B (zh) * 2017-06-07 2020-06-19 广州帝奇医药技术有限公司 一种抗帕金森病药物的长效缓释制剂及其制备方法
EP3784227A4 (en) * 2018-04-25 2022-03-02 Neurocentria, Inc. MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES
EP3883550B1 (en) 2018-11-19 2025-03-26 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations
SG11202112464PA (en) * 2019-05-31 2021-12-30 Denali Therapeutics Inc Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment
KR20210014289A (ko) 2019-07-30 2021-02-09 (주)비씨월드제약 라사길린을 함유하는 서방출성 미립구의 제조방법
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación
EP4337176B1 (en) * 2021-05-11 2025-07-16 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN117355296A (zh) * 2021-05-11 2024-01-05 阿德维斯尼公司 用于口服施用舒噻美的延长释放药物组合物
CN118680910B (zh) * 2024-08-26 2024-12-03 山东齐都药业有限公司 用于缓释递送雷沙吉兰甲磺酸盐的药物组合物及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192808A (en) 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5225446A (en) 1990-08-31 1993-07-06 Deprenyl Animal Health, Inc. Use of 1-deprenyl for retention of specific physiological functions
US5151449A (en) 1990-08-31 1992-09-29 Deprenyl Animal Health, Inc. Use of L-deprenyl for retention of specific physiological functions
US5169868A (en) 1991-03-01 1992-12-08 University Of Saskatchewan Aliphatic propargylamines as specific mao-b inhibitors
WO1992017169A1 (en) 1991-04-04 1992-10-15 The University Of Toronto Innovations Foundation Use of deprenyl to maintain, prevent loss, or recover nerve cell function
WO1992021333A2 (en) 1991-05-24 1992-12-10 Pharmavene, Inc. Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5242950A (en) 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
CA2275425C (en) 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
US5840979A (en) 1997-07-14 1998-11-24 University Of Saskatchewan Aliphatic propargylamines as cellular rescue agents
CA2372073A1 (en) 1999-04-29 2000-11-09 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycine cleavage system inhibitors as potential antipsychotics
BR0211317A (pt) * 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
US20040076668A1 (en) 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
SI1567152T1 (sl) * 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
EP1715843A1 (en) * 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
RS20070512A (sr) * 2005-06-29 2009-01-22 Panacea Biotec Ltd., Farmaceutske kompozicije sa zadržanim otpuštanjem i postupci za njihovo dobijanje
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
DK1909766T3 (en) * 2005-07-28 2016-04-04 Shire Llc PHARMACEUTICAL FORMULATIONS / FORMATIONS OF guanfacine SUITABLE FOR DAILY ADMINISTRATION IN SINGLE DOSE FORM
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
CN101486655A (zh) * 2008-01-17 2009-07-22 美德（江西）生物科技有限公司 甲磺酸雷沙吉兰晶形及其制备方法
RU2540470C9 (ru) 2008-06-06 2015-07-20 Фарма Ту Б Лтд. Фармацевтические композиции для лечения болезни паркинсона
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
US20100041920A1 (en) * 2008-07-18 2010-02-18 Stephen Benedict David Winter New salt forms of an aminoindan derivative
EP2218444A3 (en) * 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US9943489B2 (en) * 2010-02-03 2018-04-17 Pharmatwob Ltd. Extended release formulations of rasagiline and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017031189A (ja) * 2010-02-03 2017-02-09 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用

Also Published As

Publication number Publication date
CA2789006A1 (en) 2011-08-11
CY1121781T1 (el) 2020-07-31
ZA201206462B (en) 2014-02-26
BR112012019374A2 (pt) 2016-05-03
US9943489B2 (en) 2018-04-17
AU2011212068A1 (en) 2012-09-20
ES2733133T3 (es) 2019-11-27
DK2531181T3 (da) 2019-07-15
SG183150A1 (en) 2012-09-27
CN102791258B (zh) 2018-05-08
EP2531181B1 (en) 2019-04-10
WO2011095973A1 (en) 2011-08-11
RU2734632C2 (ru) 2020-10-21
PT2531181T (pt) 2019-07-17
TR201909277T4 (tr) 2019-07-22
CA2789006C (en) 2018-11-27
RU2012136723A (ru) 2014-03-10
BR112012019374B1 (pt) 2022-01-11
JP2019048855A (ja) 2019-03-28
RU2016141314A3 (cg-RX-API-DMAC10.html) 2019-12-20
KR101791715B1 (ko) 2017-10-30
KR20120130292A (ko) 2012-11-30
MX354423B (es) 2018-03-02
NZ602111A (en) 2014-10-31
PL2531181T3 (pl) 2019-09-30
JP2017031189A (ja) 2017-02-09
CL2012002175A1 (es) 2013-01-11
JP6770564B2 (ja) 2020-10-14
CN102791258A (zh) 2012-11-21
RS58988B1 (sr) 2019-08-30
RU2016141314A (ru) 2018-12-14
EP3517103A1 (en) 2019-07-31
LT2531181T (lt) 2019-07-10
US20120301542A1 (en) 2012-11-29
EP2531181A1 (en) 2012-12-12
RU2607595C2 (ru) 2017-01-10
JP6440662B2 (ja) 2018-12-19
MX2012009079A (es) 2012-12-17
JP2013518870A (ja) 2013-05-23
HUE044221T2 (hu) 2019-10-28
AU2011212068B2 (en) 2016-08-18
IL221274A0 (en) 2012-10-31
IL221274A (en) 2017-05-29

Similar Documents

Publication Publication Date Title
JP6440662B2 (ja) ラサギリンの持続放出性製剤およびその使用
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
KR102276896B1 (ko) 파킨슨병의 고정용량 조합 치료법
CA2758556A1 (en) Pharmaceutical composition of amphetamine mixed salts
US9504657B2 (en) Fixed dose combination therapy of Parkinson's disease
RU2771522C9 (ru) Терапия болезни паркинсона с применением комбинации с фиксированными дозами
HK1203847B (en) Fixed dose combination therapy of parkinson's disease
EP2886110A1 (en) Multi-layered, multiple unit pharmaceutical compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161115

R150 Certificate of patent or registration of utility model

Ref document number: 6045347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250